Neurology 2000;55:61-65
© 2000 American Academy of Neurology
Articles
The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS
A. M. Saindane, BA,
Y. Ge, MD,
J. K. Udupa, PhD,
J. S. Babb, PhD,
L. J. Mannon, RT and
R. I. Grossman, MD
From the Department of Radiology (Drs. Sandaine, Ge, Udupa, Mannon, and Grossman), Hospital of the University of Pennsylvania; and the Department of Biostatistics (Dr. Babb), Fox Chase Cancer Center, Philadelphia, PA.
Address correspondence and reprint requests to Dr. Robert I. Grossman, Department of Radiology, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA 19104; e-mail: grossman{at}oasis.rad.upenn.edu
OBJECTIVE: To determine the relationship between gadolinium-enhancing lesions and changes in whole brain parenchymal volume in patients with relapsing-remitting MS, and to test the hypothesis that gadolinium enhancement is a predictor of whole brain atrophy.
METHODS: Twenty-four patients with clinically definite MS were imaged over 2 years. A computer-assisted segmentation technique based on high-resolution MRI was used to quantify gadolinium-enhancing T1 lesion volume and brain parenchyma and CSF volumes. Percent brain parenchymal volume (PBV) relative to the total intracranial volume was calculated, and changes in PBV were used to represent the degree of whole brain atrophy over 2 years.
RESULTS: PBV at baseline was dependent on duration of MS, and a significant decrease in PBV was observed over the course of the study. Changes in enhanced T1 lesion load failed to correlate with changes in PBV, and multiple regression analyses determined that enhanced T1 lesion load at baseline was not a significant predictor of subsequent change in PBV.
CONCLUSIONS: MR visible inflammation as demonstrated by enhanced T1 lesions is not a significant factor in the pathogenesis of whole brain atrophy in relapsing-remitting MS, suggesting that a more global pathologic process is responsible for the loss of brain parenchymal volume.
This article has been cited by other articles:
|
|
|
|
 
W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, A J Thompson, and D H Miller
Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study
Multiple Sclerosis,
March 1, 2007;
13(2):
178 - 185.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Jasperse, A. Minneboo, V. de Groot, N. F. Kalkers, P. E. van Helden, B. M. J. Uitdehaag, F. Barkhof, and C. H. Polman
Determinants of Cerebral Atrophy Rate at the Time of Diagnosis of Multiple Sclerosis
Arch Neurol,
February 1, 2007;
64(2):
190 - 194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Richert, T. Howard, J. A. Frank, R. Stone, J. Ostuni, J. Ohayon, C. Bash, and H. F. McFarland
Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis
Neurology,
February 28, 2006;
66(4):
551 - 556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sastre-Garriga, G. T. Ingle, D. T. Chard, M. Cercignani, L. Ramio-Torrenta, D. H. Miller, and A. J. Thompson
Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study
Brain,
June 1, 2005;
128(6):
1454 - 1460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Versijpt, J C Debruyne, K J Van Laere, F De Vos, J Keppens, K Strijckmans, E Achten, G Slegers, R A Dierckx, J Korf, et al.
Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study
Multiple Sclerosis,
April 1, 2005;
11(2):
127 - 134.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans, M. Clanet, E. W. Radue, L. Kappos, and for the European IFNss-1a in Relapsing MS Dose Com
Rate of brain atrophy in relapsing MS decreases during treatment with IFN{beta}-1a
Neurology,
January 25, 2005;
64(2):
236 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland
Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients
Neurology,
March 9, 2004;
62(5):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R. A. Rudick, M. Kooijmans-Coutinho, M. Clanet, E. W. Radue, and L. Kappos
Atrophy Is Detectable Within a 3-Month Period in Untreated Patients With Active Relapsing Remitting Multiple Sclerosis
Arch Neurol,
December 1, 2003;
60(12):
1736 - 1739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E L. Hoogervorst, C H Polman, and F Barkhof
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone
Multiple Sclerosis,
October 1, 2002;
8(5):
415 - 419.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R Leigh, J Ostuni, D Pham, A Goldszal, B K Lewis, T Howard, N Richert, H McFarland, and J A Frank
Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences
Multiple Sclerosis,
October 1, 2002;
8(5):
420 - 429.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. F. Kalkers, N. Ameziane, J. C. J. Bot, A. Minneboo, C. H. Polman, and F. Barkhof
Longitudinal Brain Volume Measurement in Multiple Sclerosis: Rate of Brain Atrophy Is Independent of the Disease Subtype
Arch Neurol,
October 1, 2002;
59(10):
1572 - 1576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
Brain,
August 1, 2002;
125(8):
1676 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Chard, C. M. Griffin, G. J. M. Parker, R. Kapoor, A. J. Thompson, and D. H. Miller
Brain atrophy in clinically early relapsing-remitting multiple sclerosis
Brain,
February 1, 2002;
125(2):
327 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zivadinov, R. A. Rudick, R. De Masi, D. Nasuelli, M. Ukmar, R. S. Pozzi-Mucelli, A. Grop, G. Cazzato, and M. Zorzon
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
Neurology,
October 9, 2001;
57(7):
1239 - 1247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saiz, E. Carreras, J. Berenguer, J. Yague, C. Martinez, P. Marin, M. Rovira, T. Pujol, T. Arbizu, and F. Graus
MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS
Neurology,
April 24, 2001;
56(8):
1084 - 1089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ebers
MRI: measure of efficacy
Brain,
November 1, 2000;
123(11):
2187 - 2188.
[Full Text]
[PDF]
|
|
|
|
